Innate Pharma SA (IPH) Stock Statistics & Valuation Metrics

Innate Pharma SA has a market cap or net worth of $164.94M. The enterprise value is €95.26M.

Innate Pharma SA has 83,830,340 shares outstanding. The number of shares has decreased by -2.65% in one year.

Innate Pharma SA’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -8.25%.

The current PE Ratio of Innate Pharma SA is -27.85. Innate Pharma SA’s PEG ratio is 0.30.

In the last 12 months, Innate Pharma SA had revenue of 51.90M and earned -7.57M in profits. Earnings per share was -0.09.

In the last 12 months, operating cash flow was -28.60M and capital expenditures -346.00K, giving a free cash flow of -28.95M billion.

Innate Pharma SA pays an annual dividend of ―, resulting in a dividend yield of ―

Innate Pharma SA upcoming earnings date is Sep 17, 2025, TBA Not Confirmed.

Innate Pharma SA as a current ratio of 3.73, with Debt / Equity ratio of 123.29%

In the past 12 months, Innate Pharma SA has paid 0.00 in taxes.

Innate Pharma SA EV to EBITDA ratio is -23.76, with an EV/FCF ratio of -5.16.

Innate Pharma SA has $91.80M in cash and marketable securities with €40.10M in debt, giving a net cash position of -$56.30M billion.

Gross margin is -58.77%, with operating margin of -24.41%, and net profit margin of -14.59%.

The average price target for Innate Pharma SA is $4.40, which is 11.43% higher than the current price. The consensus rating is Moderate Buy